|
Video: What is a Stock Split?
|
|
EPIRUS Biopharmaceuticals is a biopharmaceutical company engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). Co.'s primary product candidate is BOW015, a biosimilar version of Remicade®. Remicade is marketed by Johnson & Johnson, Merck Schering and Mitsubishi Tanabe for the treatment of various inflammatory diseases. Co.'s biosimilar product candidates also includes BOW050, a biosimilar version of Humira®, which is marketed by AbbVie and used to treat inflammatory diseases, and BOW070, a biosimilar version of Actemra®, which is marketed by Genentech/Roche and used to treat inflammatory diseases. BOW050 and BOW070 are in preclinical development. According to our EPRS split history records, EPRS has had 1 split. | |
|
EPRS (EPRS) has 1 split in our EPRS split history database. The split for EPRS took place on July 16, 2014. This was a 1 for 10 reverse split, meaning for each 10 shares of EPRS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as EPRS conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the EPRS split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into EPRS shares, starting with a $10,000 purchase of EPRS, presented on a split-history-adjusted basis factoring in the complete EPRS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
08/03/2016 |
|
Start price/share: |
$10.40 |
|
End price/share: |
$0.14 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.65% |
|
Average Annual Total Return: |
-85.03% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$134.58 |
|
Years: |
2.27 |
|
|
|
Date |
Ratio |
07/16/2014 | 1 for 10 |
|
|